Analgesics
Antiandrogens
Antihistamines
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
TMPRSS2 inh.
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchTocilizumabTocilizumab (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta

 

The association of interleukin‐6 value, interleukin inhibitors, and outcomes of patients with COVID‐19 in New York City

Maeda et al., Journal of Medical Virology, doi:10.1002/jmv.26365, Jul 2020
https://c19early.org/maeda.html
Mortality 0% Improvement Relative Risk Tocilizumab for COVID-19  Maeda et al.  LATE TREATMENT Is late treatment with tocilizumab beneficial for COVID-19? Retrospective 224 patients in the USA No significant difference in mortality c19early.org Maeda et al., J. Medical Virology, Jul 2020 Favorstocilizumab Favorscontrol 0 0.5 1 1.5 2+
Retrospective 224 hospitalized COVID-19 patients in the USA, showing no significant difference in mortality with tocilizumab.
Standard of Care (SOC) for COVID-19 in the study country, the USA, is very poor with very low average efficacy for approved treatments1. Only expensive, high-profit treatments were approved for early treatment. Low-cost treatments were excluded, reducing the probability of early treatment due to access and cost barriers, and eliminating complementary and synergistic benefits seen with many low-cost treatments.
risk of death, no change, OR 1.00, p = 1.00, treatment 23, control 201, propensity score weighting, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Maeda et al., 28 Jul 2020, retrospective, USA, peer-reviewed, 4 authors.
DOI record: { "DOI": "10.1002/jmv.26365", "ISSN": [ "0146-6615", "1096-9071" ], "URL": "http://dx.doi.org/10.1002/jmv.26365", "abstract": "<jats:title>Abstract</jats:title><jats:p>Since cytokine release syndrome with elevation of interleukin‐6 (IL‐6) is considered to be associated with severe cases of coronavirus disease 2019 (COVID‐19); IL‐6 inhibitors, such as tocilizumab, are expected to be effective for its treatment. This was a retrospective study using a consecutive cohort of 224 patients hospitalized with COVID‐19 in March 2020. Patients were divided into those admitted to the intensive care unit (ICU group) and those not (no ICU group), and clinical data including usage of tocilizumab were compared. Correlation between IL‐6 value at admission and at peak, and tocilizumab use, as well as clinical outcomes were also investigated. The ICU group had higher rates of pre‐existing comorbidities such as hypertension, diabetes, and coronary disease, and higher IL‐6 than no ICU group (all <jats:italic>P</jats:italic> &lt; .05). Age, peak IL‐6, and peak d‐dimer were significant predictors of in‐hospital mortality (1.05 [1.01‐1.09], <jats:italic>P</jats:italic> = .012; 1.001 [1.000‐1.002], <jats:italic>P</jats:italic> = .002; 1.10 [1.03‐1.18], <jats:italic>P</jats:italic> = .008). Receiver operating characteristics curve showed higher predictability of in‐hospital mortality with IL‐6 at peak than others (area under curve; IL‐6 at peak: 0.875 [0.87‐0.942], IL‐6 at admission: 0.794 [0.699‐0.889], d‐dimer at peak 0.787 [0.690‐0.883], d‐dimer at admission 0.726 [0.625‐0.827]). Incidence of fungal infections was significantly higher in patients who were given tocilizumab than those who were not (13.0% vs 1.1%, <jats:italic>P</jats:italic> &lt; .001). Notably, tocilizumab did not affect in‐hospital mortality after adjustment including IL‐6 (odds ratio [95% confidential interval]: 1.00 [0.27‐3.72, <jats:italic>P</jats:italic> = .998]). Age, peak IL‐6, and peak d‐dimer levels were significant predictors of in‐hospital mortality. Tocilizumab did not decrease in‐hospital mortality in our cohort.</jats:p>", "alternative-id": [ "10.1002/jmv.26365" ], "assertion": [ { "group": { "label": "Publication History", "name": "publication_history" }, "label": "Received", "name": "received", "order": 0, "value": "2020-06-01" }, { "group": { "label": "Publication History", "name": "publication_history" }, "label": "Accepted", "name": "accepted", "order": 1, "value": "2020-06-26" }, { "group": { "label": "Publication History", "name": "publication_history" }, "label": "Published", "name": "published", "order": 2, "value": "2020-08-25" } ], "author": [ { "affiliation": [ { "name": "Department of Medicine, Icahn School of Medicine at Mount Sinai Mount Sinai Beth Israel New York City New York" } ], "family": "Maeda", "given": "Tetsuro", "sequence": "first" }, { "affiliation": [ { "name": "Department of Medicine, Icahn School of Medicine at Mount Sinai Mount Sinai Beth Israel New York City New York" } ], "family": "Obata", "given": "Reiichiro", "sequence": "additional" }, { "affiliation": [ { "name": "Department of Medicine, Icahn School of Medicine at Mount Sinai Mount Sinai Beth Israel New York City New York" } ], "family": "Rizk DO", "given": "Dahlia", "sequence": "additional" }, { "ORCID": "https://orcid.org/0000-0002-2487-8366", "affiliation": [ { "name": "Department of Medicine, Icahn School of Medicine at Mount Sinai Mount Sinai Beth Israel New York City New York" } ], "authenticated-orcid": false, "family": "Kuno", "given": "Toshiki", "sequence": "additional" } ], "container-title": "Journal of Medical Virology", "container-title-short": "Journal of Medical Virology", "content-domain": { "crossmark-restriction": true, "domain": [ "onlinelibrary.wiley.com" ] }, "created": { "date-parts": [ [ 2020, 7, 28 ] ], "date-time": "2020-07-28T11:14:15Z", "timestamp": 1595934855000 }, "deposited": { "date-parts": [ [ 2023, 9, 3 ] ], "date-time": "2023-09-03T09:54:24Z", "timestamp": 1693734864000 }, "indexed": { "date-parts": [ [ 2025, 5, 9 ] ], "date-time": "2025-05-09T18:44:44Z", "timestamp": 1746816284099, "version": "3.37.3" }, "is-referenced-by-count": 34, "issue": "1", "issued": { "date-parts": [ [ 2020, 8, 25 ] ] }, "journal-issue": { "issue": "1", "published-print": { "date-parts": [ [ 2021, 1 ] ] } }, "language": "en", "license": [ { "URL": "http://onlinelibrary.wiley.com/termsAndConditions#vor", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2020, 8, 25 ] ], "date-time": "2020-08-25T00:00:00Z", "timestamp": 1598313600000 } } ], "link": [ { "URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fjmv.26365", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.26365", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://onlinelibrary.wiley.com/doi/full-xml/10.1002/jmv.26365", "content-type": "application/xml", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.26365", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "311", "original-title": [], "page": "463-471", "prefix": "10.1002", "published": { "date-parts": [ [ 2020, 8, 25 ] ] }, "published-online": { "date-parts": [ [ 2020, 8, 25 ] ] }, "published-print": { "date-parts": [ [ 2021, 1 ] ] }, "publisher": "Wiley", "reference": [ { "DOI": "10.1056/NEJMoa2001017", "doi-asserted-by": "publisher", "key": "e_1_2_7_2_1" }, { "key": "e_1_2_7_3_1", "unstructured": "Coronavirus COVID‐19 global cases by the center for systems science and enginerring at Johns Hopkins University.https://coronavirus.jhu.edu/map.html" }, { "DOI": "10.1136/bmj.m606", "doi-asserted-by": "publisher", "key": "e_1_2_7_4_1" }, { "DOI": "10.1016/S0140-6736(20)30183-5", "doi-asserted-by": "publisher", "key": "e_1_2_7_5_1" }, { "DOI": "10.1136/annrheumdis-2020-217523", "doi-asserted-by": "publisher", "key": "e_1_2_7_6_1" }, { "DOI": "10.1002/jmv.25948", "doi-asserted-by": "publisher", "key": "e_1_2_7_7_1" }, { "DOI": "10.1093/eurheartj/ehaa035", "doi-asserted-by": "publisher", "key": "e_1_2_7_8_1" }, { "DOI": "10.1001/jama.2016.0287", "doi-asserted-by": "publisher", "key": "e_1_2_7_9_1" }, { "DOI": "10.1016/j.ijantimicag.2020.105949", "doi-asserted-by": "publisher", "key": "e_1_2_7_10_1" }, { "DOI": "10.1016/S0140-6736(20)30566-3", "doi-asserted-by": "publisher", "key": "e_1_2_7_11_1" }, { "DOI": "10.1136/bmj.m1333", "doi-asserted-by": "publisher", "key": "e_1_2_7_12_1" }, { "DOI": "10.1056/NEJMp1213844", "doi-asserted-by": "publisher", "key": "e_1_2_7_13_1" }, { "DOI": "10.2215/CJN.10181014", "doi-asserted-by": "publisher", "key": "e_1_2_7_14_1" }, { "DOI": "10.1001/jamainternmed.2020.0994", "doi-asserted-by": "publisher", "key": "e_1_2_7_15_1" }, { "DOI": "10.1016/j.ajem.2019.158387", "doi-asserted-by": "publisher", "key": "e_1_2_7_16_1" }, { "DOI": "10.1002/phar.2355", "doi-asserted-by": "publisher", "key": "e_1_2_7_17_1" }, { "DOI": "10.1136/bmj.m1849", "doi-asserted-by": "publisher", "key": "e_1_2_7_18_1" }, { "DOI": "10.1016/j.ijid.2020.02.043", "doi-asserted-by": "publisher", "key": "e_1_2_7_19_1" }, { "DOI": "10.1097/CCM.0b013e3181d41d45", "doi-asserted-by": "publisher", "key": "e_1_2_7_20_1" }, { "DOI": "10.1002/jmv.26149", "doi-asserted-by": "publisher", "key": "e_1_2_7_21_1" }, { "DOI": "10.1016/j.jcv.2020.104444", "doi-asserted-by": "publisher", "key": "e_1_2_7_22_1" }, { "DOI": "10.1002/jmv.25964", "doi-asserted-by": "publisher", "key": "e_1_2_7_23_1" }, { "DOI": "10.1002/jmv.26038", "doi-asserted-by": "publisher", "key": "e_1_2_7_24_1" }, { "DOI": "10.1016/j.ijantimicag.2020.105954", "doi-asserted-by": "publisher", "key": "e_1_2_7_25_1" }, { "DOI": "10.1186/s13063-020-04447-3", "doi-asserted-by": "publisher", "key": "e_1_2_7_26_1" } ], "reference-count": 25, "references-count": 25, "relation": {}, "resource": { "primary": { "URL": "https://onlinelibrary.wiley.com/doi/10.1002/jmv.26365" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "The association of interleukin‐6 value, interleukin inhibitors, and outcomes of patients with COVID‐19 in New York City", "type": "journal-article", "update-policy": "https://doi.org/10.1002/crossmark_policy", "volume": "93" }
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit